Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of AK138D1 alone or combined with ivonescimab in advanced breast cancer
CTR20261781Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AK138D1, ivonescimab in breast cancer, sponsored by Akeso, Inc.. Started Jun 2026; status: active.
02
Drugs
AK138D1ivonescimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20261781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261781.